ANDA 91588, held by Pharmaco. Montelukast Sodium.
As of Nov 21, 2026, ANDA 91588 (Montelukast Sodium), held by Pharmaco, was first approved by FDA on Aug 3, 2012, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2012 | Original application | Approved |
| Montelukast SodiumEQ 4MG BASE · tablet, chewable;oral | Montelukast Sodium | Discontinued |
| Montelukast SodiumEQ 5MG BASE · tablet, chewable;oral | Montelukast Sodium | Discontinued |
| Jun 13, 2025 | Supplement 21Labeling · Standard review | Approved | None posted |
| Jun 13, 2025 | Supplement 20Labeling · Standard review | Approved | None posted |
| Oct 2, 2020 | Supplement 19Labeling · Standard review | Approved | None posted |
| Oct 2, 2020 | Supplement 17Labeling · Standard review | Approved | None posted |
| Jul 27, 2018 | Supplement 14Labeling · Standard review | Approved | None posted |
| Jun 22, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 22, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Jul 22, 2013 | Supplement 5Labeling · Standard review | Approved | None posted |
| Dec 13, 2012 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 12, 2012 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 3, 2012 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters